ABSTRACT
Results: Flow cytometry identified a blast population demonstrating a B-cell lineage and myeloperoxidase positivity.
A P2RY8-CRLF2 fusion and JAK1 mutation were detected, both of which are associated with Ph-like features.
Conclusions: To our knowledge, this is the first report of Ph-like MPAL, which may represent a new diagnostic entity. We emphasize the need for refinement of diagnostic criteria for MPALs and highlight an opportunity for expansion of inclusion criteria in ongoing clinical trials studying the use of tyrosine kinase inhibitor therapy to include cases of Ph-like MPAL.
Mixed-phenotype acute leukemias (MPALs), characterized by leukemic cells expressing multiple lineage markers on single-or dual-cell populations, can be further classified by genetic criteria-namely, the presence of t(9;22)(q34;q11.2) BCR-ABL1 (the Philadelphia chromosome, or Ph) or t(v;11q23) KMT2A (MLL) rearrangement. 1 Similarly, B-lymphoblastic leukemias (B-ALLs) can also contain these and other disease-classifying genetic alterations. Within B-ALLs, a relatively newly recognized subtype shows a similar gene expression profile to BCR-ABL1-positive cases [2] [3] [4] and has been designated as the provisional entity "B-lymphoblastic leukemia/lymphoma, BCR-ABL1-like" in the 2016 revision to the World Health Organization (WHO) classification. 5 Cases with this alteration have an adverse prognosis and are frequently found to have translocations involving tyrosine kinase genes, including ABL1, PDGFRB, CSF1R, EPOR, and JAK2 Upon completion of this activity you will be able to:
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with over 35 different partner genes. 6, 7 In addition, almost half of BCR-ABL1-like cases show CRLF2 rearrangements, and approximately half of CRLF2-rearranged cases have concomitant mutations in the Janus kinases JAK1 or JAK2. 8 A high frequency of deletions of IKZF1 and CDKN2A/B is also seen, as it is in other types of acute lymphoblastic leukemia (ALL). 3 It has been proposed that given the unique features of the Ph-like signature, cases exhibiting characteristic translocations may be susceptible to inhibition of JAK or other kinase signaling pathways (using inhibitors such as ruxolitinib, imatinib, and dasatinib), [6] [7] [8] making identification of these "Ph-like" gene rearrangements potentially relevant for therapeutic management. However, the existence of these rearrangements has not been described outside of the context of B-ALL. Furthermore, ongoing ambiguity in the appropriate classification of mixed-phenotype leukemias has created difficulty for pathologists, clinicians, and researchers in accurately identifying these neoplasms. Here, we report, to our knowledge, the first case of a MPAL with Ph-like features, raising important implications regarding the diagnosis, classification, and treatment of these entities.
Materials and Methods

Microscopy
Formalin-fixed, paraffin-embedded (FFPE) tissue blocks were cut in 4-μm-thick sections and stained with H&E. Bone marrow aspirates were stained using WrightGiemsa stain and myeloperoxidase cytochemical staining.
Immunohistochemistry
FFPE tissue blocks were cut in 4-μm-thick sections and processed for immunohistochemistry. Staining was performed with myeloperoxidase (MPO) antibody (Ventana cat. 760-2659, rabbit polyclonal, prediluted) using the Ventana BenchMark ULTRA automated immunostainer with the Ventana ultraView DAB (diaminobenzidine tetrahydrochloride) kit for detection (Ventana Medical Systems, Tucson, AZ). Conditions of MPO staining include heat-induced epitope retrieval at 95°C with Cell Conditioning 1 (Ventana Medical Systems) for 8 minutes (pH 8.5 buffer) and 20-minute primary antibody incubation at 37°C. The counterstain was Harris hematoxylin.
Flow Cytometry
The antibodies used for analysis are as follows: CD45-R phycoerythrin-Texas Red-X (ECD), CD34-fluorescein isothiocyanate (FITC), CD33-phycoerythrin (PE), CD14-R phycoerythrin-cyanin 5.1 (PC5), CD3-FITC, CD2-PE, CD56-PC5, CD7-FITC, CD117-PE, CD20-FITC, CD5-PE, CD38-FITC, CD19-PE, CD10-PC5, CD22-FITC, CD11c-PE, CD13-PE, MPO-FITC, and CD79a-PE (Beckman Coulter, Miami, FL) and TdT-FITC (Supertechs, Rockville, MD). Heparin-anticoagulated bone marrow aspirates (1-2 mL) underwent two rounds of RBC lysis using 0.9% ammonium chloride. The samples were washed twice with standard buffer (phosphate-buffered saline, 10% sodium azide, and 1% heat-inactivated fetal bovine solution). Antibody cocktails were prepared using the Prep-Plus II instrument (Beckman Coulter) according to the manufacturer's protocol. A cell count was performed, and the sample was brought to a concentration of 10,000 cells/µL in standard buffer. Then, 50 µL of this preparation was added to each antibody cocktail. The sample was incubated for 10 minutes in the dark, washed once with standard buffer, and then fixed in 2% paraformaldehyde. Where indicated, a permeabilization step would be added to tubes that required evaluation for cytoplasmic staining. For MPO, CD22, and CD3, the Intra-Prep kit (Beckman Coulter) was used per the manufacturer's instructions. For TdT, a permeabilization buffer using 0.006% saponin (Sigma-Aldrich, St Louis, MO) in standard buffer was used. After 30 minutes at 4°C, the cells were washed and resuspended in standard buffer. The samples were then run on a Gallios 10-color calibrated flow cytometer (Beckman Coulter) using Gallios software 1.2.
Cytogenomic Array
Genomic DNA was extracted from the diagnostic bone marrow aspirate sample using the QIAamp DNA mini extraction kit (Qiagen, Germantown, MD) according to the manufacturer's instructions. Genomewide array analysis was performed using the Affymetrix CytoScan HD platform with approximately 2.7 million probes according to the manufacturer's protocols, and data were analyzed using the Affymetrix ChAS software (Affymetrix, Santa Clara, CA) as published previously. 
Fluorescent In Situ Hybridization Analysis
Fluorescent in situ hybridization (FISH) analysis was performed using the CRLF2 break-apart probe (Cytocell, Cambridge, England) to confirm the P2RY8-CRLF2 fusion. A normal cell will show two fusion signals, while a cell with a P2RY8-CRLF2 fusion will show one fusion and one green signal. Two hundred interphase nuclei were scored.
Molecular Analysis
A bone marrow aspirate sample was evaluated by Genoptix (Carlsbad, CA) using a next-generation © American Society for Clinical Pathology AJCP / Original article sequencing panel that interrogates the coding regions of 75 genes (including JAK1, JAK2, P2RY8, and IKZF1; CRLF2 not included) known to be recurrently mutated in lymphoid malignancies, as well as selected introns of six genes (ALK1, BCL2, BCL6, PDGFRB, ETV6, and MYC). According to the method listed in their report, the presence or absence of alterations is determined using comparison to databases, including COSMIC (Catalogue of Somatic Mutations in Cancer) and dbSNP (database of single nucleotide polymorphisms). Their quality control metrics include a minimum of 200 ng genomic DNA and average mean sequencing depth of ×500 coverage, giving a limit of detection of 5% for single-nucleotide variants, 10% for indels and translocation fusions, gene amplifications of six or more copies, and homozygous gene deletion of less than 0.3 copies.
Results
A 22-year-old man sought treatment for a 1-month history of dyspnea on exertion, with subsequent development of headaches, lightheadedness, and, eventually, gingival bleeding. A CBC showed anemia (hemoglobin A peripheral blood smear showed circulating blasts representing 46% of WBCs. Bone marrow biopsy specimen showed approximately 100% cellularity comprising smallto medium-sized blasts with a high nuclear to cytoplasmic ratio, round to irregular nuclei, fine chromatin, variably prominent nucleoli, and scant basophilic cytoplasm ❚Image 1A❚ and ❚Image 1B❚.
Flow cytometry detected a dim CD45+ moderate CD19+ blast population coexpressing the following (intensity and percentages of positive events within the blast population shown in parentheses): CD34 (dim-81%), CD10 (dim, minor subset-5%), CD20 (dim, minor subset-4%), cytoplasmic CD22 (dim, minor subset-20%), cytoplasmic CD79a (moderate-63%), cytoplasmic myeloperoxidase (dim to moderate-78%), and no additional antigens. Diffusely positive immunohistochemical staining for MPO was also seen in the core biopsy specimen ❚Image 1C❚. Cytochemical staining for MPO was seen in approximately 50% of blasts ❚Image 1D❚.
Cytogenetic analysis demonstrated a normal male karyotype, and FISH analysis found no evidence of BCR-ABL1 fusion or KMT2A gene rearrangement. However, a subsequent cytogenomic array analysis using the Affymetrix CytoScan platform detected multiple submicroscopic deletions involving the CDKN2A, CDKN2B, ARID2, PAN3, ATP10A, CRLF2, and P2RY8 genes, all of which are recurrent in B-ALL. The deletion at the pseudoautosomal region 1 was 327 kb in size, with the proximal breakpoint occurring within intron 1 of the P2RY8 gene and the distal breakpoint occurring within the coding region of the CRLF2 gene, producing a 5ʹ P2RY8-3ʹ CRLF2 fusion ❚Image 2A❚. The deletion was further confirmed by using CRLF2 break-apart FISH to show deletion of the 5ʹ CRLF2 probe ❚Image 2B❚. The array also detected a deletion of 29 kb, including exon 1 of the CDKN2A gene and partial exon 2 of the CDKN2B gene. Molecular analysis performed at a reference laboratory detected a JAK1 V658F mutation. The overall findings were therefore consistent with an MPAL, B/myeloid with a concomitant P2RY8-CRLF2 fusion and a JAK1 mutation.
The patient was treated with the C8811 (Larson) protocol with the addition of rituximab. A day 34 bone marrow biopsy specimen showed residual disease with 30% to 40% blasts. He was then treated with the "B" arm of hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) together with ruxolitinib, given the JAK1 mutation, again without response. He also did not respond to one cycle of blinatumomab or to clofarabine, cyclophosphamide, and etoposide chemotherapy. At the time of this writing, he is being screened for CAR (chimeric antigen receptor) T-cell-based therapy as part of a clinical trial.
Discussion
To our knowledge, this case represents the first report of a Ph-like MPAL. It raises the possibility that analogous to the MPALs and B-ALLs with BCR-ABL1, there may be both MPALs and B-ALLs that are BCR-ABL1-like. Currently, the provisional "BCR-ABL1-like" appellation specifically applies to B-ALL only, which puts the present case in a somewhat ambiguous diagnostic category.
The nuances of accurately diagnosing and classifying acute leukemias with these genetic lesions and immunophenotypic characteristics merit further consideration. Low-level flow cytometric evidence of MPO positivity in otherwise typical B-ALLs has been described in up to 8% to 9% of cases, and more recent evidence suggests that it heralds a poor outcome. 5, [10] [11] [12] Nonspecific immunohistochemical staining of B-ALL cases with polyclonal MPO antibody has also been reported. 13 However, the 2016 WHO revision has cautioned against the diagnosis of MPAL in cases of otherwise typical B-ALL when immunophenotypic MPO positivity is the sole myeloid-defining criterion. 5 In the present case, cytochemical staining (observed in approximately 50% of blasts) was particularly helpful in confirming the presence of true MPO positivity (Image 1D). However, while a 3% threshold of MPO positivity is the current standard for assigning myeloid lineage by cytochemistry, 1 there is currently no consensus regarding an analogous threshold for flow cytometric immunophenotyping. 12 Suggested cutoffs of 10% positivity 14 or relative positivity compared with background lymphocytes 15 have been proposed.
This case raises the question of whether otherwise typical B-ALL cases warrant further evaluation for a mixed phenotype. Because such cases are not always investigated thoroughly for expression of myeloid markers (especially MPO), it is possible that some cases of B-ALL, including Ph-like B-ALL, may actually represent cases of MPAL. 12 The studies that initially identified Ph-like signatures in B-ALL 2-4 do not make a distinction between cases with and without MPO expression, and MPO status is not specifically addressed in the published data. It would be interesting to revisit the cohorts in those studies and see if any cases technically may have also met criteria for MPAL.
While our case demonstrates a true mixed phenotype, its overall genetic profile more closely resembles that of a B-ALL. As described above, cytogenomic analysis identified multiple genetic mutations, all of which are recurrent ❚Image 1❚ Histopathologic findings diagnostic of mixed-phenotype acute leukemia. A, Bone marrow aspirate with numerous blasts (Wright-Giemsa, ×100 oil). B, Bone marrow core biopsy specimen shows extensive involvement by leukemia (H&E, ×20 dry). C, Myeloperoxidase immunohistochemistry demonstrates diffuse positivity (Ventana cat. 760-2659, rabbit polyclonal, prediluted, ×20 dry). D, Myeloperoxidase cytochemistry demonstrates granular positivity in peripheral areas of the cytoplasm as well as some granules overlying the nucleus (×100 oil). All images were acquired using cellSens imaging software, Olympus DP72 camera, on an Olympus BX41 upright microscope (Olympus, Center Valley, PA).
in B-ALL. Of note, molecular analysis also detected a CDKN2A alteration (C.151-6delTinsCCAGGGG), which has not been reported previously and is of unclear significance. 16 How these immunophenotypic and genetic changes affect the biologic behavior of this leukemia remains to be seen.
Thus far, the patient has not responded to any therapeutic regimens, including one using the JAK2 inhibitor ruxolitinib. Whether (or if) MPALs demonstrate the same frequency of Ph-like cases as B-ALLs is an open and interesting question. In our own institutional experience, of three MPAL cases evaluated using the cytogenomic array, only the present case demonstrated a Ph-like signature (unpublished data).
Whether all MPAL cases warrant testing for Ph-like signatures is difficult to assess, given the relative paucity of knowledge about the effectiveness of kinase inhibitor therapy, even in Ph-like B-ALL, that exists at this time. Nevertheless, the possibility of targeted agents, particularly in cases refractory to standard therapies, and the prognostic implications of a Ph-like signature suggest that comprehensive testing could be considered in all MPAL cases. What this comprehensive testing should entail is, at present, an open question since gene expression profiling, the method by which Ph-like B-ALL cases have been defined historically, is not readily available, occurs primarily in a research/clinical trial setting, and can show variation. 3, 7 As a result, other surrogate assays (eg, FISH, flow cytometry, capture-based RNA sequencing, next-generation sequencing, or cytogenomic array in our case) are being used as a way of identifying these cases. 6, 7 FISH analysis, in particular, has been proposed as a straightforward and cost-effective method for identifying common kinase gene alterations that are associated with the Ph-like signature. 17 However, a number of these methods are limited in the scope of what they are able to detect, and no single method currently has the ability to detect every Ph-like alteration. The timely identification of this signature is necessary to administer an appropriate upfront treatment regimen.
7
Because Ph-like B-ALL is a new entity, its identification and the methods used to define it are currently not standardized as part of routine practice and are instead predominantly relevant in the setting of clinical trials that are evaluating the therapeutic efficacy of kinase inhibitors, such as dasatanib and ruxolitinib. 7 However, the patient populations in these clinical trials are, at present, restricted to B-ALL only, and inclusion criteria invariably do not include MPALs. Again, the current case raises the question of whether some cases of MPAL are potentially unknowingly being included or excluded due to ambiguity of diagnostic classification. On a deeper level, it raises the fundamental question of what exactly defines a disease that exhibits such genetic heterogeneity and complexity.
In conclusion, this case highlights a potential novel diagnostic and therapeutically relevant entity of which both pathologists and treating physicians should be aware when evaluating new patients with B-ALL or MPAL. Given the ongoing need for definitive clinical trials to address the role of kinase inhibition in patients with Ph-like leukemias, careful introspection as to whether ❚Image 2❚ P2RY8-CRLF2 fusion was detected by array and confirmed by CRLF2 break-apart fluorescent in situ hybridization analysis. A, The 327-kb deletion within pseudoautosomal region 1 juxtaposes exon 1 of P2RY8 to the coding region of CRLF2 gene, resulting in P2RY8-CRLF2 fusion. B, The deletion was confirmed by CRLF2 break-apart FISH showing deletion of the 5ʹ CRLF2 probe (orange). Arrow indicates loss of 5ʹ CRLF2 probe (orange signal), leaving the remaining 3ʹ probe (green signal).
